Dimitri P. Mikhailidis, Moses Elisaf, Manfredi Rizzo, Kaspar Berneis, Bruce Griffin, Alberto Zambon, Vasilios Athyros, Jacqueline de Graaf, Winfried Marz, Klaus G. Parhofer, Giovam Battista Rini, Giatgen A. Spinas, Gerald H. Tomkin, Alexandros D. Tselepis, Anthony S. Wierzbicki, Karl Winkler, Matilda Florentin and Evangelos Liberopoulos Pages 533 - 571 ( 39 )
Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density lipoproteins (LDL) subclasses. We sub-divided our Statement in 2 sections: section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drugs and lifestlyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.
LDL, subclasses, atherosclerosis, cardiovascular risk, statement, hypertriglyceridaemia, coronary heart disease, cardiovascular disease, apolipoprotein, chylomicrons
Department of Clinical Biochemistry, Royal Free Hospital Campus, University College Medical School, University College London (UCL), Pond Street, London NW3 2QG, UK.